ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

REDUCTION IN BLEEDS FOLLOWING
SWITCH FROM FIX ON-DEMAND¹¹

A retrospective chart review across six haemophilia treatment centres in the US for patients with haemophilia B switching from previous FIX on-demand treatment to ALPROLIX prophylaxis reported:¹¹

Numerical decrease in bleed rates¹¹

Switching to ALPROLIX prophylaxis numerically reduced median bleed rates vs pre-switch FIX on-demand¹¹

Median bleed rates pre- and post-switch (n=10)*¹¹

Adapted from Shapiro A, et al. 2020.¹¹
p-value not reported

Target joint outcomes¹¹

At the end of the chart review period,
32% (17/53)
of target joints had resolved¹¹

Overall, 47% (n=9/19) of patients did not report a target joint¹¹

66% (n=19/29) of patients receiving FIX on-demand prior to initiating ALPROLIX had switched to ALPROLIX prophylaxis at the end of the chart review period¹¹

• Median (range) follow-up for all patients receiving ALPROLIX was 2.7 (0.5–5.0) years

*Included patients who had available ABR data pre- and post-switch to ALPROLIX prophylaxis.¹¹
ABR, annualised bleeding rate; AjBR, annualised joint bleeding rate; AsBR, annualised spontaneous bleeding rate; FIX, factor IX; IQR, interquartile range; OD, on-demand.

KEY SAFETY OUTCOMES¹¹

Specific adverse events that were collected and recorded during ALPROLIX
therapy included hypersensitivity (including anaphylaxis), nephrotic syndrome and
thrombosis/thromboembolism. Other adverse events were not collected in this review¹¹

Reported safety outcome:

One patient experienced an AE of hypersensitivity,
which was not associated with inhibitor development¹¹

AE, adverse event; FIX, factor IX.

REDUCTION IN BLEEDS FOLLOWING
SWITCH FROM FIX ON-DEMAND¹¹

*The primary objective was to understand the clinical characteristics and outcomes resulting from the real-world management of patients with haemophilia B being treated with ALPROLIX. The study period for retrospective data collection was 12 months prior to ALPROLIX initiation until the date of site initiation.¹¹
ABR, annualised bleeding rate; FIX, factor IX.